Crocs, Inc.
CROX
$127.77
+5.90%
Crocs, Inc. is a global footwear company primarily known for its distinctive, comfortable, and casual lifestyle clogs, sandals, and accessories for men, women, and children, operating within the Apparel - Footwear & Accessories industry. The company has established itself as a market leader in the casual comfort segment, with its Crocs brand achieving iconic status, and has expanded its portfolio through the acquisition of the HEYDUDE brand, which focuses on lightweight, casual shoes. The current investor narrative is heavily focused on the company's recent earnings beat and the strategic plan to revitalize the underperforming HEYDUDE brand, which has driven significant stock price volatility and debate over whether the current valuation fully reflects the turnaround potential or underlying risks.…
CROX
Crocs, Inc.
$127.77
Related headlines
Investment Opinion: Should I buy CROX Today?
Rating & Thesis: Hold. CROX presents a high-risk, high-reward proposition where compelling valuation (forward P/E of 8.38) and strong cash flow are counterbalanced by significant operational uncertainty and a technically overextended stock price. The neutral-to-hold analyst consensus reflects this balanced but cautious outlook.
Supporting Evidence: The primary valuation metric, the forward P/E of 8.38 and PEG of 0.52, suggests deep undervaluation if earnings estimates of $14.83 are achieved. The company's robust free cash flow generation ($659.2M TTM) and operating margin (21.97%) provide a financial safety net. However, these positives are offset by declining revenue (-3.25% YoY), high stock price volatility (beta of 1.538), and the stock trading at 99.3% of its 52-week high, indicating limited near-term upside without a fundamental catalyst.
Risks & Conditions: The two biggest risks are the failure of the HEYDUDE turnaround, leading to further revenue misses, and a technical reversal from overbought levels triggering a sharp correction. This Hold rating would upgrade to a Buy if the stock pulls back to support (e.g., below $100) while HEYDUDE shows sequential quarterly improvement, or if forward revenue estimates are revised upward. It would downgrade to a Sell if QoQ revenue growth turns negative again or if gross margins fall below 50%. Based on its forward multiples versus its volatile earnings profile, the stock is fairly valued for the risk it presents.
Sign up to view all
CROX 12-Month Price Forecast
CROX is a classic 'show me' story at a value price. The bullish argument rests almost entirely on the successful execution of the HEYDUDE turnaround, which would justify significant multiple expansion from today's depressed levels. The bearish argument points to concrete revenue weakness and the stock's extended technical position after a massive rally. The high free cash flow and low forward P/E provide a compelling valuation floor, but the high beta and operational uncertainty cap the near-term upside. The stance would upgrade to bullish on evidence of HEYDUDE stabilization (sequential revenue growth) or a pullback to the $100-$110 range. It would turn bearish if the next earnings report shows further gross margin compression or a guidance cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crocs, Inc.'s 12-month outlook, with a consensus price target around $166.10 and implied upside of +30.0% versus the current price.
Average Target
$166.10
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$102 - $166
Analyst target range
Analyst coverage appears limited, with only 3 analysts providing estimates for revenue and EPS, and the institutional ratings data shows a mixed but cautious sentiment with recent actions including a downgrade to 'Sector Weight' from Keybanc and a shift to 'Neutral' from Baird. The consensus, inferred from the ratings, leans neutral-to-hold with firms like Stifel and Barclays maintaining 'Hold' or 'Equal Weight' ratings, though Needham maintains a 'Buy'. The estimated EPS range of $14.53 to $15.12 and revenue range of $4.49 billion to $4.63 billion for the forward period provides a target framework, but explicit price targets are not provided in the data. The wide dispersion in analyst actions—from Buy to Sell—and the limited number of covering analysts signals high uncertainty and potentially less efficient price discovery, which is consistent with the stock's high beta and recent extreme volatility.
Bulls vs Bears: CROX Investment Factors
The bull and bear cases for CROX are sharply divided, with the bear side currently holding stronger evidence based on concrete financial results. The most compelling bear arguments are the recent revenue decline and the significant operational risk tied to the HEYDUDE brand turnaround, which is a material part of the business. However, the bull case is supported by powerful technical momentum, deeply discounted valuation multiples, and robust underlying cash generation. The single most important tension in the investment debate is the resolution of the HEYDUDE brand's performance. If management's revitalization plan succeeds, the stock's low forward P/E of 8.38 and depressed PS ratio could expand dramatically, driving significant upside. If the plan fails, the current revenue decline could accelerate, margins could compress further, and the stock's high beta could magnify the downside from its extended technical position.
Bullish
- Strong Technical Momentum & Breakout: The stock has surged +41.30% over the past three months and +18.05% over the past month, significantly outperforming the S&P 500. This powerful breakout from a lower base suggests a major shift in sentiment, likely driven by optimism around the HEYDUDE turnaround plan and recent earnings beat.
- Attractive Forward Valuation Multiples: The stock trades at a forward P/E of 8.38 and a forward Price-to-Sales ratio of approximately 1.02, based on analyst revenue estimates. The PEG ratio of 0.52, based on this forward P/E, suggests the stock is undervalued relative to its expected earnings growth, presenting a compelling entry point if the growth narrative materializes.
- Robust Cash Generation & Shareholder Returns: The company generated $659.2 million in TTM free cash flow and $252.53 million in operating cash flow last quarter. This strong cash flow supports financial health, debt management, and shareholder returns, evidenced by $180.17 million in stock repurchases in Q4 2025.
- Core Brand Stability & Healthy Margins: Despite recent revenue headwinds, the core Crocs brand maintains a solid gross margin profile, with the latest quarterly figure at 54.68%. The company's operating margin of 21.97% indicates underlying profitability and operational efficiency in its primary business segment.
Bearish
- Revenue Decline & HEYDUDE Integration Risk: Q4 2025 revenue declined -3.25% YoY to $957.64 million, highlighting growth challenges. The HEYDUDE brand, contributing $189.26M (20% of revenue), is the primary source of volatility and uncertainty, as its underperformance necessitates a costly and uncertain turnaround strategy.
- High Volatility & Elevated Technical Risk: With a beta of 1.538, the stock is 54% more volatile than the market, and it has experienced a maximum drawdown of -38.97%. Trading at 99.3% of its 52-week high ($122.33), the recent parabolic move leaves it vulnerable to a sharp technical pullback if momentum falters.
- Inconsistent Profitability & Negative TTM EPS: Trailing twelve-month EPS is negative at -$0.02, driven by a significant loss in Q2 2025. While quarterly results have improved, this inconsistency and the sequential decline in gross margin from 58.52% in Q3 to 54.68% in Q4 raise concerns about earnings quality and sustainability.
- Mixed & Limited Analyst Sentiment: Analyst coverage is limited to only 3 firms, with recent actions including a downgrade to 'Sector Weight' and a shift to 'Neutral'. This mixed, cautious sentiment and lack of broad coverage indicate high uncertainty and less efficient price discovery, increasing stock-specific risk.
CROX Technical Analysis
The stock is in a strong, sustained uptrend, evidenced by a 1-year price change of +22.74% and a more pronounced 6-month gain of +35.47%. As of the latest close at $121.52, the stock is trading near the top of its 52-week range, approximately 99.3% of the way from its 52-week low of $73.21 to its high of $122.33, indicating significant momentum but also potential overextension. Recent momentum has been exceptionally strong, with the stock surging +18.05% over the past month and +41.30% over the past three months, far outpacing the S&P 500's gains of +4.6% and +12.6% over the same periods, respectively, signaling accelerating bullish sentiment and a powerful breakout from earlier consolidation. Key technical support is anchored at the 52-week low of $73.21, while immediate resistance is at the 52-week high of $122.33; a confirmed breakout above this level could signal a continuation of the uptrend, while a failure could lead to a pullback. The stock's beta of 1.538 indicates it is approximately 54% more volatile than the broader market, which is a critical consideration for risk management given the stock's recent parabolic move and a maximum drawdown of -38.97% observed in the provided data.
Beta
1.56
1.56x market volatility
Max Drawdown
-39.0%
Largest decline past year
52-Week Range
$73-$129
Price range past year
Annual Return
+25.0%
Cumulative gain past year
| Period | CROX Return | S&P 500 |
|---|---|---|
| 1m | +23.3% | -0.1% |
| 3m | +58.9% | +9.0% |
| 6m | +43.0% | +7.0% |
| 1y | +25.0% | +22.9% |
| ytd | +46.9% | +8.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CROX Fundamental Analysis
Revenue growth has been inconsistent, with the most recent quarterly revenue of $957.64 million representing a year-over-year decline of -3.25%. However, segment data reveals a bifurcated story: the core Crocs Brand generated $768.38 million, while the HEYDUDE Brand contributed $189.26 million, indicating the latter is a significant but potentially troubled growth vector that management is actively addressing. The company remains profitable on an operating basis, with Q4 2025 net income of $105.17 million and a robust gross margin of 54.68%, though this marks a sequential decline from the 58.52% gross margin reported in Q3 2025, suggesting some margin pressure. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.25, but financial health is supported by strong cash generation, evidenced by trailing twelve-month free cash flow of $659.2 million and an operating cash flow of $252.53 million in the latest quarter, providing ample liquidity for debt service and shareholder returns like the $180.17 million in stock repurchases noted in Q4.
Quarterly Revenue
$957640000.0B
2025-12
Revenue YoY Growth
-0.03%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$659200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CROX Overvalued?
Given the trailing twelve-month net income is negative at -$0.02 per share, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 1.15, while the forward-looking valuation, implied by analyst estimates for $4.56 billion in revenue, suggests a forward PS of approximately 1.02, indicating the market expects modest sales growth and potentially improved efficiency. Compared to historical averages, the current PS ratio of 1.15 is near the lower end of its multi-year range, which has seen figures above 4.5 as recently as late 2025, suggesting the stock may be pricing in significant pessimism or a fundamental reset, particularly around the HEYDUDE segment. The forward PE ratio of 8.38, based on estimated EPS of $14.83, appears low and is supported by a PEG ratio of 0.52, which could indicate undervaluation if the company's growth and margin recovery plans are successfully executed.
PE
-57.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -3x~16x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CROX faces significant financial risk from the inconsistent profitability of its HEYDUDE segment, which contributed 20% of Q4 revenue ($189.26M) but is the primary driver of overall revenue declining -3.25% YoY. The company's moderate debt-to-equity ratio of 1.25 is manageable but becomes a concern if cash flow weakens during the brand's turnaround. Furthermore, the sequential gross margin compression from 58.52% in Q3 to 54.68% in Q4 signals potential pricing pressure or product mix issues that could threaten the core brand's robust profitability, which is critical for funding the HEYDUDE fix.
Market & Competitive Risks: The stock's high beta of 1.538 makes it exceptionally sensitive to market downturns, and its current price near the 52-week high ($122.33) leaves it vulnerable to valuation compression, especially if growth expectations are not met. The limited analyst coverage (only 3 firms) and mixed sentiment, including recent downgrades, exacerbate this volatility and suggest the market narrative is fragile. Competitive risks are heightened as the company must execute a complex brand turnaround in the crowded casual footwear market while maintaining the momentum of its core Crocs brand, all under the scrutiny of a volatile stock price.
Worst-Case Scenario: The worst-case scenario involves a failure of the HEYDUDE turnaround plan, leading to sustained revenue declines and further margin erosion. This could trigger analyst downgrades, a loss of investor confidence, and a rapid derating of the stock's valuation multiples. Combined with a broader market pullback, this could catalyze a sharp sell-off toward the 52-week low of $73.21. From the current price of $121.52, this represents a potential downside of approximately -40%. The stock's history of a -38.97% maximum drawdown demonstrates its capacity for such severe corrections, especially given its high volatility.
FAQ
The key risks are, in order of severity: 1) Operational: Failure of the HEYDUDE brand turnaround, evidenced by the segment's drag on Q4 revenue which declined -3.25% YoY. 2) Financial: Inconsistent profitability, with TTM EPS negative at -$0.02 and sequential gross margin compression. 3) Market: Extreme stock price volatility, with a beta of 1.54 and a history of a -38.97% drawdown, magnifying losses in a downturn. 4) Sentiment: Limited and mixed analyst coverage increases uncertainty and the potential for sharp reactions to earnings misses.
The 12-month forecast is bifurcated, with a 50% probability base case target of $110-$130, a 30% probability bull case target of $140-$160, and a 20% probability bear case target of $73-$95. The base case, which is most likely, assumes the HEYDUDE brand stabilizes without major improvement, revenue meets analyst consensus of ~$4.56B, and the stock's current forward P/E of ~8x holds. The bull case requires a successful turnaround driving multiple expansion, while the bear case involves further operational deterioration. The wide range reflects the stock's high beta (1.54) and binary outcome tied to the HEYDUDE segment.
Based on forward-looking metrics, CROX appears significantly undervalued. Its forward P/E ratio of 8.38 and PEG ratio of 0.52 are deeply discounted, especially for a company with a 21.97% operating margin. The forward Price-to-Sales ratio of ~1.02 is also near the low end of its historical range, which has been above 4.5. This discount reflects the market's skepticism about the HEYDUDE brand and recent revenue weakness. Therefore, the stock is undervalued if management executes its turnaround, but the low multiple is a warranted risk premium for the current operational uncertainty.
CROX is a high-risk, high-potential-reward stock that may be a good buy for speculative investors comfortable with volatility. The forward P/E of 8.38 and PEG ratio of 0.52 suggest significant undervaluation if the company's earnings and turnaround plans materialize. However, with revenue declining -3.25% YoY, the stock trading at 99.3% of its 52-week high, and a beta of 1.54, the near-term risk of a sharp pullback is elevated. It is a good buy for investors who believe in the HEYDUDE turnaround and are willing to hold through volatility, but a poor choice for conservative investors seeking stability.
CROX is more suitable for a medium-to-long-term investment horizon (12-24 months) rather than short-term trading. The investment thesis is fundamentally driven by the multi-quarter execution of the HEYDUDE turnaround plan, which will not be resolved in a few weeks. The stock's high beta of 1.54 makes it prone to severe short-term swings unrelated to fundamentals, which could punish traders. Long-term investors can potentially look through this volatility to capture the valuation upside if the plan succeeds. A minimum holding period of 12-18 months is suggested to allow for several quarterly reports that provide evidence for or against the turnaround narrative.